ATE368051T1 - Angiostatinfragmente und verfahren für deren verwendung - Google Patents

Angiostatinfragmente und verfahren für deren verwendung

Info

Publication number: ATE368051T1
Authority: AT; Austria
Prior art keywords: angiostatin; fragments; methods; proliferation inhibitor; aggregate
Prior art date: 1995-04-26

Application number

AT96913208T

Other languages

English (en)

Inventor

M Folkman

Michael O'reilly

Yihai Cao

Jie Lin

Original Assignee

Childrens Medical Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-26

Filing date

1996-04-26

Publication date

2007-08-15

1995-04-26 Priority claimed from US08/429,743 external-priority patent/US5885795A/en

1996-02-22 Priority claimed from US08/605,598 external-priority patent/US5861372A/en

1996-03-08 Priority claimed from US08/612,788 external-priority patent/US5837682A/en

1996-04-26 Application filed by Childrens Medical Center filed Critical Childrens Medical Center

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE368051T1 publication Critical patent/ATE368051T1/de

Links

102000012936 Angiostatins Human genes 0.000 title abstract 6
108010079709 Angiostatins Proteins 0.000 title abstract 6
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 title abstract 6
239000012634 fragment Substances 0.000 title abstract 5
239000003112 inhibitor Substances 0.000 abstract 3
230000004663 cell proliferation Effects 0.000 abstract 2
210000002889 endothelial cell Anatomy 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
102000013566 Plasminogen Human genes 0.000 abstract 1
108010051456 Plasminogen Proteins 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
230000002491 angiogenic effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000003511 endothelial effect Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Oncology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT96913208T 1995-04-26 1996-04-26 Angiostatinfragmente und verfahren für deren verwendung ATE368051T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/429,743 US5885795A (en)	1994-04-26	1995-04-26	Methods of expressing angiostatic protein
US08/605,598 US5861372A (en)	1996-02-22	1996-02-22	Aggregate angiostatin and method of use
US08/612,788 US5837682A (en)	1996-03-08	1996-03-08	Angiostatin fragments and method of use

Publications (1)

Publication Number	Publication Date
ATE368051T1 true ATE368051T1 (de)	2007-08-15

Family

ID=27411639

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96913208T ATE368051T1 (de)	1995-04-26	1996-04-26	Angiostatinfragmente und verfahren für deren verwendung

Country Status (16)

Country	Link
EP (1)	EP0824546B1 (de)
JP (2)	JP3787157B2 (de)
CN (1)	CN1195375A (de)
AT (1)	ATE368051T1 (de)
AU (1)	AU709633B2 (de)
BR (1)	BR9608326A (de)
CA (1)	CA2219081C (de)
CZ (1)	CZ334097A3 (de)
DE (1)	DE69637179T2 (de)
ES (1)	ES2292174T3 (de)
HU (1)	HUP9800784A3 (de)
MX (1)	MX9708217A (de)
NO (1)	NO974943L (de)
NZ (1)	NZ307044A (de)
PL (1)	PL323256A1 (de)
WO (1)	WO1996035774A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945403A (en) *	1997-05-30	1999-08-31	The Children's Medical Center Corporation	Angiostatin fragments and method of use
US6358735B1 (en)	1995-06-30	2002-03-19	University Of Kansas Medical Center	Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en)	1995-06-30	2002-08-27	University Of Kansas Medical Center	Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
CZ298612B6 (cs) *	1995-12-13	2007-11-21	The Children's Medical Center Corporation	Inhibitor proliferace endothelových bunek a jeho použití
US5801012A (en)	1996-09-17	1998-09-01	Northwestern University	Methods and compositions for generating angiostatin
CA2303401A1 (en) *	1997-10-01	1999-04-08	G.D. Searle & Co.	Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
WO1999026480A1 (en) *	1997-11-20	1999-06-03	Genetix Pharmaceuticals, Inc.	Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
CA2313251A1 (en) *	1997-12-08	1999-06-17	Beth Israel Deaconess Medical Center	Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
US6797488B1 (en)	1997-12-08	2004-09-28	Beth Israel Deaconess Medical Center	Methods of producing anti-angiogenic proteins
CA2263784A1 (en)	1998-03-23	1999-09-23	Megabios Corporation	Dual-tagged proteins and their uses
DE69939586D1 (de) *	1998-04-28	2008-10-30	Toshikazu Nakamura	Inhibitoren für die gefässneubildung
WO1999061464A1 (en) *	1998-05-28	1999-12-02	Korea Green Cross Corporation	Process of purifying angiogenesis inhibitors
AU762615B2 (en)	1998-06-15	2003-07-03	Arch Development Corporation	Combination of radiotherapy and anti-angiogenic factors
US6201104B1 (en) *	1998-12-04	2001-03-13	Entremed, Inc.	Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000044391A2 (en) *	1999-01-28	2000-08-03	The Children's Medical Center Corporation	Plasminogen kringle 4 region fragments and methods of use
DE60034434T2 (de) *	1999-02-10	2008-01-10	The Children's Medical Center Corp., Boston	Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
US7157556B1 (en)	1999-02-10	2007-01-02	The Children's Medical Center Corporation	Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
PE20020376A1 (es) *	2000-09-29	2002-05-13	Abbott Lab	Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
AU2003226349B2 (en) *	2002-04-11	2008-01-31	Children's Medical Center Corporation	Methods for inhibiting vascular hyperpermeability
KR100681762B1 (ko) *	2004-01-09	2007-02-15	재단법인 목암생명공학연구소	인간 아포리포단백질(ａ) 크링글 ＬＫ68 또는 ＬＫ8유전자를 유효성분으로 함유하는 항암 치료제 및 그를이용한 암 치료방법
CA2557154A1 (en) *	2004-02-24	2005-09-01	Ttc Co., Ltd.	Anticancer agent containing bl-angiostatin
ITMI20041962A1 (it) *	2004-10-15	2005-01-15	Istituto Naz Per La Ricerca S	"peptide di angiostatina e suoi impieghio terapeutici"
CN101219219B (zh) *	2007-01-10	2013-02-13	北京普罗吉生物科技发展有限公司	包含血管抑素或其片段的复合物、其制备方法及应用
WO2010070746A1 (ja) *	2008-12-17	2010-06-24	株式会社ティムス	イヌアンジオスタチン様ポリペプチド
JP5749229B2 (ja) *	2012-07-31	2015-07-15	京セラドキュメントソリューションズ株式会社	ジェスチャー管理プログラム及び情報処理装置
CN106890324A (zh) *	2015-12-18	2017-06-27	深圳瑞健生命科学研究院有限公司	一种预防和治疗糖尿病肾病的方法
DK3395354T3 (da)	2015-12-18	2024-06-03	Talengen Int Ltd	Plasminogen til anvendelse i behandling af diabetisk nefropati
CN110198732A (zh)	2016-12-15	2019-09-03	泰伦基国际有限公司	一种促进胰岛素受体底物-2表达的方法
SG11202001595SA (en) *	2017-08-31	2020-03-30	Singapore Health Serv Pte Ltd	Angio-3 for treatment of retinal angiogenic diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE355379T1 (de) *	1994-04-26	2006-03-15	Childrens Medical Center	Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese

1996
- 1996-04-26 NZ NZ307044A patent/NZ307044A/en not_active IP Right Cessation
- 1996-04-26 PL PL96323256A patent/PL323256A1/xx unknown
- 1996-04-26 BR BR9608326-3A patent/BR9608326A/pt unknown
- 1996-04-26 CN CN96194077A patent/CN1195375A/zh active Pending
- 1996-04-26 AT AT96913208T patent/ATE368051T1/de active
- 1996-04-26 HU HU9800784A patent/HUP9800784A3/hu unknown
- 1996-04-26 EP EP96913208A patent/EP0824546B1/de not_active Expired - Lifetime
- 1996-04-26 ES ES96913208T patent/ES2292174T3/es not_active Expired - Lifetime
- 1996-04-26 CA CA002219081A patent/CA2219081C/en not_active Expired - Lifetime
- 1996-04-26 MX MX9708217A patent/MX9708217A/es unknown
- 1996-04-26 CZ CZ973340A patent/CZ334097A3/cs unknown
- 1996-04-26 AU AU55795/96A patent/AU709633B2/en not_active Expired
- 1996-04-26 DE DE69637179T patent/DE69637179T2/de not_active Expired - Lifetime
- 1996-04-26 JP JP53410496A patent/JP3787157B2/ja not_active Expired - Lifetime
- 1996-04-26 WO PCT/US1996/005856 patent/WO1996035774A2/en not_active Ceased
1997
- 1997-10-24 NO NO974943A patent/NO974943L/no not_active Application Discontinuation
2000
- 2000-10-06 JP JP2000308481A patent/JP2001151691A/ja active Pending

Also Published As

Publication number	Publication date
JP3787157B2 (ja)	2006-06-21
DE69637179T2 (de)	2008-04-10
CA2219081C (en)	2004-02-24
NO974943D0 (no)	1997-10-24
DE69637179D1 (de)	2007-09-06
NZ307044A (en)	2002-03-01
JPH11508228A (ja)	1999-07-21
BR9608326A (pt)	2000-03-08
HUP9800784A2 (hu)	1998-07-28
CA2219081A1 (en)	1996-11-14
HK1002457A1 (en)	1998-08-28
EP0824546B1 (de)	2007-07-25
AU5579596A (en)	1996-11-29
AU709633B2 (en)	1999-09-02
EP0824546A2 (de)	1998-02-25
CN1195375A (zh)	1998-10-07
WO1996035774A3 (en)	1997-02-13
JP2001151691A (ja)	2001-06-05
NO974943L (no)	1997-12-18
ES2292174T3 (es)	2008-03-01
PL323256A1 (en)	1998-03-16
HUP9800784A3 (en)	2000-07-28
CZ334097A3 (cs)	1998-04-15
WO1996035774A2 (en)	1996-11-14
MX9708217A (es)	1997-12-31

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 0824546

Country of ref document: EP

Publication	Publication Date	Title
ATE368051T1 (de)	2007-08-15	Angiostatinfragmente und verfahren für deren verwendung
CA2291892A1 (en)	1998-12-03	Angiostatin fragments and method of use
Shirasuna et al.	1993	Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation
ATE354372T1 (de)	2007-03-15	Verwendung von mif-antagonisten zur krebstherapie
EA199800391A1 (ru)	1999-10-28	Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
ATE402698T1 (de)	2008-08-15	Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE214075T1 (de)	2002-03-15	Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
DE69818049D1 (de)	2003-10-16	Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
PT1019040E (pt)	2005-01-31	Inibicao da actividade de p38-quinase por meio de arilureias
DE69815090D1 (de)	2003-07-03	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60015070D1 (de)	2004-11-25	Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
EP1064308A4 (de)	2004-08-11	Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE60019321D1 (de)	2005-05-12	Verfahren zum screening von inhibitoren von asp2
ATE250077T1 (de)	2003-10-15	Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung
DE60044350D1 (de)	2010-06-17	Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
DE69615843D1 (de)	2001-11-15	Il-8 antagonisten zur behandlung von asthma
ATE211921T1 (de)	2002-02-15	Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
WO2000044391A3 (en)	2000-12-21	Plasminogen kringle 4 region fragments and methods of use
ATE265526T1 (de)	2004-05-15	Genetisch veränderte fibroblasten und ihre verwendung
ATE229339T1 (de)	2002-12-15	Inhibitor der immunoglobulin e antikörpererzeugung zur behandlung von typ i allergie-verwandten krankheiten
IS5613A (is)	2000-08-30	Notkun CD137 til að stuðla að fjölgun jaðar-einkjörnunga
EP1102599A4 (de)	2004-03-17	Protease hemmstoffe zur verwendung in der behandlung von psoriasis
CO4920227A1 (es)	2000-05-29	Histidina-n-bencil glicinamida sustituida con cicloalquilos .
TR199901543T2 (xx)	1999-09-21	Benzo $F] kinolinnonlar�n sentezi
ATE271878T1 (de)	2004-08-15	Verwendung von protein h als zytostattischer wirkstoff